On the evening of the 28th, Walvax Biotechnology Co.Ltd(300142) announced that it would jointly carry out product development and commercial cooperation with blue magpie biology on the mRNA vaccine of covid-19 virus variant strain.
The reporter noted that in 2020, Walvax Biotechnology Co.Ltd(300142) will “hand in hand” Aibo biological layout covid-19 mRNA vaccine. Just a few days ago, the phase I clinical data of the vaccine were released, which preliminarily verified that the vaccine was safe, controllable and manageable, and had preliminary immunogenicity. However, the adverse reaction rate disclosed in the experimental data has attracted the attention of the outside world.
Is the selection of two partners for covid-19 vaccine products based on mRNA technology affected by the above clinical data? In response, Walvax Biotechnology Co.Ltd(300142) responded that the company has been cooperating with external companies based on products. If the next round of epidemic outbreak or new mutants appear, it can choose products with faster response and higher protection.
